Next-generation Sequencing for Outbreak Investigation in the Clinical Microbiology Laboratory
American Society for Clinical Laboratory Science · 2019-04 · 32 (2) · 70-77
DOI: 10.29074/ascls.2019001750 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Society for Clinical Laboratory Science, online erschienen am 07.02.2023. Verfasst von Caitlin E. Dougherty und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
With the advent of next-generation sequencing technologies, genomic investigations of pathogen outbreaks are now possible at unprecedented resolution. Prior methods requiring highly pathogen-specific protocols can now be replaced with a single universal protocol for whole-genome sequencing. Clinical applications have shown improvement in our understanding of pathogen transmission dynamics from the hospital to global level. However, there are several barriers to routine implementation in clinical microbiology laboratories. These include financial support for a nonbillable test; workforce training needs, particularly for highly complex data analysis methods; and lack of Food and Drug Administration–approved methods requiring extensive laboratory validation.
Zitieren
APA
Dougherty, C. E., & Graf, E. (2019). Next-generation Sequencing for Outbreak Investigation in the Clinical Microbiology Laboratory. American Society for Clinical Laboratory Science, 32(2), 70-77. https://doi.org/10.29074/ascls.2019001750
Vancouver
Dougherty CE, Graf E. Next-generation Sequencing for Outbreak Investigation in the Clinical Microbiology Laboratory. American Society for Clinical Laboratory Science. 2019;32(2):70-77. doi:10.29074/ascls.2019001750
BibTeX
@article{Dougherty2019,
author = {Dougherty, Caitlin E. and Graf, Erin},
title = {Next-generation Sequencing for Outbreak Investigation in the Clinical Microbiology Laboratory},
journal = {American Society for Clinical Laboratory Science},
year = {2019},
volume = {32},
number = {2},
pages = {70--77},
doi = {10.29074/ascls.2019001750}
}
EUVIMED